Monday, 31 August, 2026
Samsung Biologics Makes $1.8B Swiss Play for GLP-1 Boom
By TechShots Studio
Samsung Biologics will launch a CHF 1.46 billion ($1.8 billion) tender offer on September 15 to acquire Swiss peptide manufacturer PolyPeptide Group. Running through October 12, the deal offers shareholders CHF 44.31 per share in cash. Backed unanimously by PolyPeptide’s board, the acquisition will expand Samsung’s CDMO business into high-demand peptide therapeutics like obesity and diabetes treatments.
Read full story at REUTERS